A peer-reviewed journal that offers evidence-based clinical information and continuing education for dentists.

Vaccine Development Continues as More Enter Distribution Phase and Clinical


With new hope emerging in the global pandemic by the roll out of two mRNA-based COVID-19 vaccines by Pfizer and Moderna, additional vaccines are entering the market and undergoing testing in large clinical trials. AstraZeneca’s COVID-19 vaccine is expected to receive approval from regulators in the United Kingdom as soon as today. The AstraZeneca vaccine uses a modified adenovirus that teaches human cells to create the novel coronavirus’ spike protein. It requires two injections but does not need to be frozen like the Pfizer and Moderna vaccines, which may ease the distribution process.

The Novavax vaccine, which uses a stabilized form of the novel coronavirus’ spike protein, began a 30,000 subject Phase 3 clinical trial in the United States and Mexico on December 28. Supported by President Trump’s Operation Warp Speed Program, the Novavax vaccine creates antibodies to SARS Co-V-2’s spike protein that hinder its ability to attach to cell surface receptors. The vaccine requires two injections but does not need to be stored in subzero temperatures. Read more here.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy